<DOC>
	<DOCNO>NCT00693615</DOCNO>
	<brief_summary>The goal study describe safety , reactogenicity immunogenicity MEDI-517 without adjuvant HPV-naïve human . Long-term immune data collect . This study originally perform MedImmune . However , GSK responsible clinical development HPV vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study MEDI-517 ( GSK 580299 ) With Without Adjuvant Healthy Adult Females</brief_title>
	<detailed_description>This Phase II , double-blind , randomize , comparative trial three formulation MEDI-517 give 0 , 30 , 180 day intramuscular injection . The volunteer study healthy female 18 30 year age . The study collect safety , reactogenicity immunogenicity data MEDI-517 without adjuvant . Extended follow-up provide long-term immune response data .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Females 18 30 year age ( must reach 31st birthday ) Written informed consent obtain volunteer Unless previously surgically sterilize , agree use effective method birth control begin 30 day first study injection continue 60 day final study injection Must negative serum pregnancy test within 21 day study entry must breast feed Healthy medical history physical examination Seronegative HPV16 HPV18 antibody ELISA within 21 day study entry Cervical specimen negative highrisk HPV DNA use Digene Hybrid Capture® II HPV test ( highrisk type Probe B ) within 21 day study entry Normal Pap smear , use Cytyc ThinPrep® Pap Test , within 21 day study entry No evidence anogenital HPV lesion physical finding suggestive gynaecologic pathogen pelvic examination within 21 day study entry Agrees vaccine experimental therapy 30 day last study injection Acute illness fever ( oral temperature ≥ 99.5°F [ 37.5°C ] ) start study History clinical manifestation significant medical psychiatric disorder Use immunosuppressive medication ( inhaled topical corticosteroid permit ) within previous 90 day history immunodeficiency History cancer History alcohol drug abuse within past 2 year Abnormal laboratory blood value screen . Other abnormal laboratory value screen panel opinion principal investigator judge clinically significant Receipt immunoglobulin blood product within 90 day prior study entry History abnormal Pap smear ( single prior report ASCUS indeterminate Pap smear subsequent normal report ) Genital herpes disease involve cervix disease characterize examination history extensive external lesion . Volunteers history recurrent genital herpes disease characterize limited external lesion eligible participate study . Positive test hepatitis C antibody , hepatitis B surface antigen , HIV1 antibody Any prior receipt vaccine ( experimental otherwise ) treatment prophylaxis genital wart papillomavirus relate condition . Any treatment genital wart papillomavirus relate condition within 6 month randomization ( local therapy common skin and/or plantar wart allow ) Previous administration component investigational vaccine Receipt experimental vaccine within 90 day prior entry study Receipt experimental drug therapy within 30 day five halflives experimental drug ( halflife know ) , whichever long</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HPV , Vaccine</keyword>
</DOC>